Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 126   

Articles published

NVO 57.64 -0.18 (-0.31%)
price chart
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch List
[The Motley Fool] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) Diabetes powerhouse Novo Nordisk A/S (ADR) (NYSE:NVO) recently presented impressive data on its type 2 diabetes drug candidate IDegLira. IDegLira is an investigational ...
The winners of healthcare stocks for 2015 : Novo Nordisk A/S (ADR) (NYSE:NVO ...  Wall Street Observer
4 Movers to Watch for:Novo Nordisk A/S (NVO), W&T Offshore (WTI ...  Techsonian (press release)
Novo Nordisk A/S (ADR) Stock Surges On Increased Profit And Sales
Novo Nordisk A/S (ADR) (NYSE:NVO) announced its earnings for the first quarter of 2015 and the financial guidance for the full year 2015, and said that its current chief executive officer, Lars Rebien Sorensen, will remain at the helm of the company ...
Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time  Benzinga
Large Cap Stocks Investor's Alert - Novo Nordisk (NVO), CVS Health (CVS ...  Techsonian (press release)
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Novo Nordisk A/S (ADR) (NYSE:NVO) close to 52-week high, short interest surging
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $56.27, up by 1.22%, with a volume of 1,155,117 shares against an average volume for the last 3 months of 1,713,340.
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch
[ZACKS] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) announced new data from a couple of studies on its approved products, Xultophy and Victoza, during the weekend.
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Call Buyers Take Aim at Surging Novo Nordisk A/S (NVO)  Schaeffers Research (blog)
Hot Stocks on the Run: Alibaba Group Holding Ltd (NYSE:BABA), Novo Nordisk A ...  wsnewspublishers
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Form 6-K NOVO NORDISK AS For: Mar 23  StreetInsider.com
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...